237 related articles for article (PubMed ID: 16638868)
1. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.
Balza E; Mortara L; Sassi F; Monteghirfo S; Carnemolla B; Castellani P; Neri D; Accolla RS; Zardi L; Borsi L
Clin Cancer Res; 2006 Apr; 12(8):2575-82. PubMed ID: 16638868
[TBL] [Abstract][Full Text] [Related]
2. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
[TBL] [Abstract][Full Text] [Related]
3. Selective targeted delivery of TNFalpha to tumor blood vessels.
Borsi L; Balza E; Carnemolla B; Sassi F; Castellani P; Berndt A; Kosmehl H; Biro A; Siri A; Orecchia P; Grassi J; Neri D; Zardi L
Blood; 2003 Dec; 102(13):4384-92. PubMed ID: 12933583
[TBL] [Abstract][Full Text] [Related]
4. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
Gorelik L; Rubin M; Prokhorova A; Mokyr MB
J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
[TBL] [Abstract][Full Text] [Related]
5. In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.
Donda A; Cesson V; Mach JP; Corradin G; Primus FJ; Robert B
Cancer Immun; 2003 Aug; 3():11. PubMed ID: 12916958
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells.
Balza E; Zanellato S; Poggi A; Reverberi D; Rubartelli A; Mortara L
Eur J Immunol; 2017 Apr; 47(4):743-753. PubMed ID: 28198545
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity.
Kianmanesh A; Hackett NR; Lee JM; Kikuchi T; Korst RJ; Crystal RG
Hum Gene Ther; 2001 Nov; 12(17):2035-49. PubMed ID: 11747595
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
Altenschmidt U; Klundt E; Groner B
J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
[TBL] [Abstract][Full Text] [Related]
9. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
10. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
Barker E; Mokyr MB
Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
[TBL] [Abstract][Full Text] [Related]
11. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
12. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
13. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy.
Saji H; Song W; Furumoto K; Kato H; Engleman EG
Clin Cancer Res; 2006 Apr; 12(8):2568-74. PubMed ID: 16638867
[TBL] [Abstract][Full Text] [Related]
14. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.
Xiang R; Lode HN; Dreier T; Gillies SD; Reisfeld RA
Cancer Res; 1998 Sep; 58(17):3918-25. PubMed ID: 9731503
[TBL] [Abstract][Full Text] [Related]
15. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
16. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
17. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
18. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
20. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
